Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer (HER2CLIMB)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02614794
Recruitment Status : Active, not recruiting
First Posted : November 25, 2015
Last Update Posted : October 7, 2019
Sponsor:
Information provided by (Responsible Party):
Seattle Genetics, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : September 2020
Estimated Study Completion Date : July 2021